For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
Basic information |
Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
Ying Chu Shih |
Rich Yuan |
Rich Yuan |
03-6587721 |
Rm.4,3F, No.6-1, Sec. 2, Shengyi Rd.,Zhubei City, Hsinchu County 302, Taiwan |
2015/10/21 |
Industrycategory |
Key businesses |
Biotechnology and Medical Care |
TaiwanJ is a specialty pharmaceutical company dedicated to the development and
commercialization of first-in-class small molecules as TLR4 antagonists. The
Company's drug development strategy is to reduce time-to-market, lower clinical
risks, and minimize development costs by re-profiling approved drugs. In
addition, the company is developing a rich pipeline of novel chemical entities
(NCEs) for therapy to address chronic liver disease, inflammatory bowel
disease, and rheumatoid arthritis, as well as organ damage to the kidney and
the lung. Specific diseases targeted include liver inflammation, liver
fibrosis, NASH, NALFD, and autoimmune diseases including rheumatoid arthritis
and Crohn’s Disease. TaiwanJ seeks product development collaborations and
strategic alliances to develop its pipeline of products into the market. |
Financial data |
Cash flows statement
| Item
|
|
|
Amount(NTD, in thousands) |
Cash flows from operating activities |
|
|
Cash flows from investing activities |
|
|
Cash flows from financing activities |
|
|
Consolidated/Individual balance sheet
|
Current assets |
|
|
Non-current assets |
|
|
Total assets |
|
|
Current liabilities |
|
|
Non-current liabilities |
|
|
Total liabilities |
|
|
Share capital |
|
|
Capital surplus |
|
|
Retained earnings |
|
|
Other equity interest |
|
|
Treasury shares |
|
|
Total equity attributable to owners of parent |
|
|
Non-controlling interests |
|
|
Total equity |
|
|
Book Value per share(NT$) |
|
|
Consolidated/Individual profit and loss statement |
Operating revenue |
|
|
Operating costs |
|
|
Gross profit from operations |
|
|
Operating expenses |
|
|
Net other income (expenses) |
|
|
Net operating income |
|
|
Non-operating income and expenses |
|
|
Profit before tax |
|
|
Tax expense |
|
|
Profit from continuing operations |
|
|
Profit from discontinued operations |
|
|
Profit |
|
|
Other comprehensive income |
|
|
Comprehensive income |
|
|
Basic earnings per share |
|
|
Auditor's report on latest financial statements: auditor's report:
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|